Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01525810 · ClinicalTrials.gov registry record
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 218
- Enrollment target
NCT01525810 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 218 participants.
The verdict
NCT01525810 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 218 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine whether the hepatitis C virus continues to remain unable to be detected in subjects who were previously treated with BMS-914143 and achieved sustained virologic response
Interventions
- DRUG Peginterferon Lambda-1a (BMS-914143)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2012-03 |
| Est. Completion | 2014-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01525810
The ClinicalTrials.gov registry entry for NCT01525810 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Peginterferon Lambda-1a (BMS-914143) is the first listed.
NCT01525810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01525810 about?
NCT01525810 is a clinical study titled "Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial". The primary purpose of this study is to determine whether the hepatitis C virus continues to remain unable to be detected in subjects who were previously treated with BMS-914143 and achieved sustained virologic response
What is the current status of trial NCT01525810?
This trial is currently completed. The enrollment target is 218 participants. The study started on 2012-03. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01525810?
The interventions under investigation include: Peginterferon Lambda-1a (BMS-914143) (DRUG).
Who is sponsoring clinical trial NCT01525810?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.